GLPG0778/555 Immuno & Inflammatory
GlaxoSmithKline has exercised its option to exclusively license investigational compound GLPG0778 and its corresponding back-up compound GLPG0555, both discovered and developed within GSKs immuno-inflammatory alliance with Galapagos. GSK will have the right to continue the clinical development of these candidate compounds.
© Copyright 2013 Galapagos NV | Disclaimer | General Purchase Terms